Company intelligence / Profile preview
PharmaDiall LLC
Russiapharmadiall.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmaDiall developed Dimolegin, an original direct oral anticoagulant targeting factor Xa. In Phase 3 trials, Dimolegin demonstrated higher efficacy than Kleksan for indications similar to those recommended for COVID symptoms by the Russian Ministry of Health. In Phase 2 trials for prevention of venous thrombosis after knee replacement surgery, it showed superior efficacy compared to Fragmin with a low rate of significant bleeding events. The drug is positioned as a potential blockbuster due to its unique pharmacokinetics and once-daily dosing.
- Therapeutic areas
- Women's HealthCardiovascular
- Modalities
- Small molecules (biologically active chemicals)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on PharmaDiall LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaDiall LLC.